D. E. Danilau

D. E. Danilau

Auto-generated profile, based on publicly available information

D. E. Danilau

Belarusian State Medical University, Minsk

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2021 in Health and Ecology Issues
Verified
Journal Article
Open access
PDF file
DDD. E. Danilau
D. E. Danilau
The article describes a clinical case of an increased level of hepatic transaminases during a delayed period of the treatment in a patient with coronavirus disease COVID-19 using remdesivir and a possible effect of hepatic steatosis on the severity of cytolytic syndrome associated with the course of COVID-19.

1 January 2020 in Hepatology and Gastroenterology
Verified
Journal Article
Open access
PDF file
DDD. E. Danilau
D. E. Danilau
Background. Worldwide, prior to 1990, a large number of patients with hemophilia were infected with the hepatitis C virus due to substitution therapy. The mortality rate from chronic liver disease and HCC in patients with HCV and hemophilia is signifcantly higher than in general population. Objective. To assess the results of direct-acting antiviral therapy in patients with hemophilia and chronic hepatitis C. Material and methods. The rate of sustained virologic response after DAA treatment and the dynamics of clinical and laboratory parameters during antiviral treatment were evaluated. Results. All 14 patients achieved sustained virological response after 12 / 24 weeks of treatment. During antiviral treatment, some patients showed an increase in blood urea nitrogen, a decrease in leukocyte count, and increase of ALT activity. All these phenomena were reversible and resolved spontaneously. Conclusion. The DAA regimens available in Belarus are highly effective for the treatment of chronic hepatitis C in patients with hemophilia. These regimens do not signifcantly affect hematological parameters, are well tolerated, and have acceptable safety profle.

20 October 2026
Verified
Journal Article
Open access
PDF file
DLD. Litvinchuk
D. Litvinchuk
DDD. Danilau
D. Danilau
IKI. Karpov
I. Karpov
ДЛД. В. Литвинчук
Д. В. Литвинчук
ДДД. Е. Данилов
Д. Е. Данилов
ИКИ. А. Карпов
И. А. Карпов
Objective. To characterize clinical severity of COVID-19 in hospitalized patients during pandemic periods and to assess the effect of vaccination on disease course. Materials and methods. Single-centre retrospective cohort study of 11,203 patients hospitalized with COVID-19 in 2020– 2023 (112,455 bed-days). Clinical severity was graded on a four-level respiratory failure scale: «none»; «oxygen mask/cannula»; «noninvasive ventilation» (NIV); «invasive mechanical ventilation» (IMV). Bayesian hierarchical ordinal regression was fitted with covariates: age, Elixhauser comorbidity index, vaccination, previous-day respiratory failure, pandemic day and disease days. Statistical analysis was performed with programming languages R 4.6.0 and Stan 2.38.0. Results. The 28-day cumulative risk of respiratory failure was up to 50 % in the first wave, up to 80 % in the period of Alpha variant predominance, > 90 % (unvaccinated) and ≤ 65 % (vaccinated) in the period of Delta variant predominance, and ≤ 25 % in the Omicron. During predominance of Delta variant, the probability of NIV/IMV reached 25–30 % in older unvaccinated patients with comorbidities compared to ≤ 4.5 % in vaccinated ones; during predominance of Omicron variants it was < 1 %, though up to 20 % still required oxygen. After standardization, vaccination was associated with a lower cumulative risk from September 2021 to March 2022, peaking in December 2021: -24.3 % (95 % CI (-17,6; -30,6)). Conclusion. Respiratory failure severity varied by pandemic period, and vaccination against SARS-CoV-2 had a protective effect in hospitalized patients.

1 January 2026 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Closed access
DLD.V. Litvinchuk
D.V. Litvinchuk
DDD.E. Danilau
D.E. Danilau
OKO.V. Krasko
O.V. Krasko
IKI.A. Karpov
I.A. Karpov